Michael McDonnell, EVP & CFO, to Retire in February 2025
Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer,…
WuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed…
Lupin Prioritizes Development of Inhalers with Eco-Friendly, Low Global Warming Propellants
Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide…
Odyssey Therapeutics to Present Data on OD-07656 at ACG Annual Scientific Meeting 2024
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein…
Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA…
Novartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial
Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G)…
Astellas Updates on European Union Marketing Authorization Application for Avacincaptad Pegol (ACP)
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the withdrawal of its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution…
Biogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in…
Dr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row
Dr. Reddy’s Laboratories Ltd. has been recognized as one of the top employers in the 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine, marking the company’s third…
enGene Secures $60 Million in Private Placement Financing
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing…
Felix Health Launches First National Menopause Show for Women in Perimenopause and Beyond
Felix Health, a virtual care provider dedicated to helping Canadians manage their everyday health needs, is excited to be the presenting sponsor of the National Menopause Show. Set to attract…
LabGenomics USA Finalizes Acquisition of IMD CLIA Labs
LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, increasing its total number of CLIA-certified labs in the U.S. to four. This acquisition enhances LabGenomics’ strategic growth and…